Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 122-125, 2023.
Artigo
em Chinês
| WPRIM
| ID: wpr-989533
ABSTRACT
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a new immune checkpoint protein. Studies have shown that TIGIT can cause dysfunction of immune cells, weaken the anti-tumor effect, thus leading to tumor immune tolerance and immune escape. Blocking TIGIT can reverse immune cell failure and exert anti-tumor effect, which is expected to become a new therapeutic target for multiple myeloma.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of International Oncology
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS